SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons sharp move is drawing attention after Morgan Stanley named it a top pick, citing accelerating AWS growth and AI opportunities; traders are also pointing to Amazons Trainium software announcement as a potential boost to cloud-chip adoption. The reaction is broadly bullish, though some remain cautious about heavy AI capital spending and whether the gains will hold.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Reports of Lundbecks interest in acquiring Xeris have fueled heavy-volume trading and takeover speculation, though the company has said it is not for sale and no deal is confirmed. Traders are split between expecting further buyer interest and viewing the chatter as unsubstantiated, while some point to Recorlev growth and XP-8121s pipeline potential as standalone reasons for optimism.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares surged after bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria, supporting a planned FDA resubmission. Traders are debating whether the move can continue, with some citing short-squeeze potential and others warning of profit-taking, safety concerns around dizziness, and the fact that FDA approval is still pending.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Recent open-market purchases by Celsius executives and directors have fueled bullish discussion around the shares, while skeptics question whether the buys signal durable confidence given concerns about the core brands sales and management execution. Traders also revive speculation about a Pepsi buyout, but no deal is confirmed.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Anticipation of Vicors Q3 earnings is driving discussion after the company raised its sequential growth outlook twice, with traders pointing to higher royalties from its Vertical Power Delivery licensing. Bulls expect the stronger outlook to show up in results, while others are wary of the sharp pullback and volatility despite the guidance increases.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix shares are under pressure as EyePoints failed wet-AMD trial has heightened doubts about TKI-based treatments, prompting traders to question whether those concerns could extend to Oculars AXPAXLI program. Some investors view the selloff as spillover from a competitors results, while others cite clinical uncertainty and the departure of Oculars chief strategy officer as additional concerns.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

The FDA-cleared expansion of Alpha Taus REGAIN trial in recurrent glioblastoma is a key focus, alongside planned trial data at SNO 2026. Traders are optimistic about early local-control results, while some note that they come from a small initial cohort; the completed enrollment of the pancreatic IMPACT study is another pipeline catalyst discussed.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

A stronger-than-guided Q3 report and an upbeat 2027 EBITDA outlook are driving CLFs rally. Bulls see improving steel prices and earnings potential, while skeptics warn that debt and the reliance on favorable price forecasts could limit the recovery; traders are also debating whether the move will hold or fade as a sell-the-news rally.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO decline dominates discussion, with traders pointing to insider selling and upcoming share unlocks alongside concerns about valuation, scaling and reliance on OpenAI amid weakness across AI stocks. Some see the selloff as an oversold buying opportunity and are averaging in, while others expect further downside.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ rebounded as technology and AI stocks recovered from a sharp selloff, with traders debating whether the move marks a durable recovery or a low-volume bull trap. Upcoming megacap earnings and AI spending plans are a key focus for the tech-heavy index.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

LMND Stock Rises Pre-Market: Morgan Stanley Backs Its Early Bet On Autonomous Vehicle Insurance

Equity

Morgan Stanley said Lemonade’s initial move into the self-driving vehicle space “represents an important first step.”

Are Tech ETFs New Safe Haven Amid Iran War?

Iran war volatility lifts oil and rattles stocks. But tech ETFs, powered by AI, cloud and cybersecurity demand, are emerging as surprising defensive plays.

Lemonade Stock Jumps Pre-Market As Morgan Stanley Upgrades On Growth Optimism: Retail Rides Along 

The brokerage praised the company’s “differentiated” AI-driven technology and its roadmap to achieve net profit positivity by the end of 2027.


Amplify ETF Trust - Amplify BlueStar Israel Technology ETF

Bearish Sentiment

<ul class="summary-bullets"><li>Morgan Stanley increased the price target for Lemonade to $85 from $80.&nbsp;</li><li>Tesla’s partnership puts the insurer ahead of competitors, Morgan Stanley says.&nbsp;</li><li>The firm indicated that pricing remains grounded in risk evaluation, suggesting a disciplined approach.</li></ul>Morgan Stanley has upgraded Lemonade Inc. (LMND) to an ‘Overweight’ rating, citing its emerging collaboration with Tesla Inc. (TSLA) as a catalyst that could reshape its long-term growth outlook.In January, the insurance provider introduced a new product for autonomous cars, initially targeting vehicles equipped with Tesla’s Full Self-Driving technology. (FSD)<a href="https://stocktwits.com/symbol/LMND">Lemonade stock</a> traded over 6% higher in Tuesday’s premarket. On Stocktwits, retail sentiment around the stock changed to ‘neutral’ from ‘bearish’ territory the previous day. Message volume shifted to ‘low’ from ‘extremely low’ message volume levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2025_08_18_092502_png_4d549e99e9.webp" alt="LMND’s Sentiment Meter and Message Volume as of 06:00 a.m. ET on Mar. 17, 2026 | Source: Stocktwits" width="947" height="108"><figcaption>LMND’s Sentiment Meter and Message Volume as of 06:00 a.m. ET on Mar. 17, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">A First Mover Bet On Autonomous Insurance&nbsp;</h2>Morgan Stanley stated that Lemonade’s early involvement in the autonomous vehicle ecosystem "represents an important first step", according to TheFly. By working alongside Tesla, the insurer gains access to real-world driving data and operational insights, positioning it ahead of competitors in a space that is still developing.&nbsp;The firm sees this as a foundational move that could unlock future opportunities as self-driving adoption expands. Morgan Stanley also increased the price target for Lemonade to $85 from $80.&nbsp;<h2 class="st-heading-2">What Does It Mean For LMND’s Earnings Story?</h2>Lemonade has introduced a pricing incentive, offering a steep 50% discount on auto coverage when Tesla’s full self-driving mode is activated. Lemonade said drivers using the feature could see per-mile costs reduced by roughly half, reflecting internal data suggesting lower accident risk during automated operation.Despite this aggressive approach, Morgan Stanley noted that the company is not compromising on underwriting standards. The firm indicated that pricing remains grounded in risk evaluation, suggesting a disciplined approach even as it experiments with new models.Analysts expect Lemonade to deepen its exposure to autonomous driving over time, which could help scale its insurance platform. Morgan Stanley also believes this trajectory could “meaningfully improve” the company’s earnings profile over the longer term.LMND stock has declined over 18% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lululemon-heads-for-first-sales-drop-in-six-years-amid-leadership-turmoil/cZ33yCfRIQ8">Lululemon Heads For First Sales Drop In Six Years Amid Leadership Turmoil</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Lemonade, Inc. is displayed on a smartphone screen, with the company's bright pink branding visible in the background, on May 04, 2025, in Chongqing, China.

Amplify Bluestar Israel Technology ETF

Lemonade Inc

Invesco Dorsey Wright Financial Momentum ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Feed

News

Sentiment

Fundamentals

Info

ITEQ Amplify Bluestar Israel Technology ETF

Fundamentals

Latest ITEQ News